IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques (Q40526097)

21 September 2017

title

IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques (English)

1 reference

21 September 2017

Villinger F

1

1 reference

21 September 2017

Miller R

2

1 reference

21 September 2017

Mori K

3

1 reference

21 September 2017

Mayne AE

4

1 reference

21 September 2017

Bostik P

5

1 reference

21 September 2017

Sundstrom JB

6

1 reference

21 September 2017

Sugimoto C

7

1 reference

21 September 2017

Ansari AA

8

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

22

1 reference

21 September 2017

issue

25-26

1 reference

21 September 2017

page(s)

3510-3521

1 reference

Costimulation in antiviral immunity: differential requirements for CD4(+) and CD8(+) T cell responses

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Regulation of the immune response by antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Effector and memory T-cell differentiation: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Cytokine modified tumor vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

IL-15 enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and CD8+ effector-memory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Homeostatic proliferation but not the generation of virus specific memory CD8 T cells is impaired in the absence of IL-15 or IL-15Ralpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Costimulatory approaches to adoptive immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

IL-15 and IL-2: a matter of life and death for T cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Effects of exogenous interleukin-7 on human thymus function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

IL-7 prevents both caspase-dependent and -independent pathways that lead to the spontaneous apoptosis of i-IEL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Induction of sensitivity to activation-induced death in primary CD4+ cells: a role for interleukin-2 in the negative regulation of responses by mature CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Hematologic and virologic effects of lineage-specific and non-lineage-specific recombinant human and rhesus cytokines in a cohort of SIVmac239-infected macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Hematopoietic response to lineage-non-specific (rrIL-3) and lineage-specific (rhG-CSF, rhEpo, rhTpo) cytokine administration in SIV-infected rhesus macaques is related to stage of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Failure to expand influenza and tetanus toxoid memory T cells in vitro correlates with disease course in SIV infected rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Immune stimulation may contribute to enhanced progression of SIV induced disease in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Chronic immune stimulation accelerates SIV-induced disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Qualitative and quantitative studies of cytokines synthesized and secreted by non-human primate peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Induction of long-term protective effects against heterologous challenge in SIVhu-infected macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Limiting dilution assays. Experimental design and statistical analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Progressive differentiation and selection of the fittest in the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

T cell immunity in lymphoid and non-lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Antiviral CD4 and CD8 T-cell memory: differences in the size of the response and activation requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Cytokines and costimulatory molecules as genetic adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Sterile protection of monkeys against malaria after administration of interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Consideration of cytokines as therapeutics agents or targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Practical aspects of cytokine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.07.022

10.1016/J.VACCINE.2003.07.022

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference